StreetAlpha.app
Home › Stocks › MBX

MBX Biosciences, Inc. (MBX)

Healthcare
$53.10
▼ −0.04%
LAST CLOSE · NOV 17

MBX Biosciences develops peptide-based drug candidates for endocrine and metabolic disorders, including a lead treatment for a rare hormone disorder. It last closed at $53.10 on Nov 17, down 0.04% on the day. The average 12-month price target from 4 analysts is $103.00 (+94.0% from the last close), with a high of $150.00 and a low of $84.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).

AI Auto Pilots
Is MBX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$145.1M
EPS (diluted)
−$3.03
−139.5% vs a year ago
Free cash flow
−$99.3M
Valuation
Market cap
$2.6B
49.7M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$161.7M
At Sep 30
Shareholder equity
$472.9M
Shares outstanding
49.7M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: −$32.6M−$32.6MFY2023FY2024: −$61.9M−$61.9MFY2024FY2025: −$87.0M−$87.0MFY2025

From MBX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on MBX in the past 90 days
Average 12-month target
$103.00
▲ 94.0% upside

Based on 4 analysts who set a price target on MBX in the past 90 days. The average target is $103.00, with a high of $150.00 and a low of $84.00, compared with the last close of $53.10.

Low $84.00Avg $103.00High $150.00
Blue marker: last close $53.10
Highest target$150.00
Average target$103.00
Lowest target$84.00
Latest rating changes
HC Wainwright & Co.Initiated
Nov 12Buy$90
StifelMaintained
Oct 12Buy$84
GuggenheimMaintained
Oct 2Buy$150
JP MorganReinstated
Aug 21Buy$88
Truist SecuritiesMaintained
Aug 10Buy$88
DateFirmActionRatingPrice target
Nov 12HC Wainwright & Co.InitiatedBuy$90
Oct 12StifelMaintainedBuy$84
Oct 2GuggenheimMaintainedBuy$150
Aug 21JP MorganReinstatedBuy$88
Aug 10Truist SecuritiesMaintainedBuy$88
Loading…

Technical Analysis

MBX · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 0% below its 20 day and 4% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 48). The nearest support is the swing low (Jul 14) at $52.51, and the nearest resistance the 20 day average at $53.36.

Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 6.9%/day
Key levels
$72.6452 week high+36.8%
$59.31100 day average+11.7%
$56.20Swing high (Oct 21)+5.8%
$55.4150 day average+4.4%
$54.05Pivot R1+1.8%
$53.3620 day average+0.5%
$53.10Last close
$52.51Swing low (Jul 14)−1.1%
$52.26Pivot−1.6%
$51.30Pivot S1−3.4%
$46.48200 day average−12.5%
$24.6852 week low−53.5%
Indicators
RSI (14)47.86Middle of its rangeNeutral
MACD-0.11Above its signal lineBullish
Stochastic59.3Middle of its rangeNeutral
ADX (14)13.4No clear trend
Williams %R-49.5Oversold below −80, overbought above −20Neutral
CCI (20)-39.3Oversold below −100, overbought above 100Neutral
Rate of change−3.5%Change over 10 sessionsBearish
ATR (14)$3.65Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for MBX

What happened before

See how MBX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in MBX in the last 90 days.

Loading…

See today’s whale options flow across the market →

MBX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲96 buying vs 81 selling
  • ●Held by funds +0.0 pts
  • ▲Funds holding +18
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding191173+10.4%
In funds' top 1098+12.5%
Held by funds111.7%111.7%0.0 pts
New / increased39 / 5736 / 62−2.0%
Reduced / sold out60 / 2147 / 20+20.9%
Put/call ratio0.001.00−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MBX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MBX is in one of them and how their past MBX trades turned out.

MBX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MBX in an article yet. Here's the latest on the wider market.

About MBX Biosciences

MBX Biosciences is a biopharmaceutical company based in Carmel, Indiana, that develops peptide medicines for hormone and metabolic conditions. Its candidates are built on a proprietary platform designed to give peptides longer action and steadier levels in the body, so they can be taken less often. The lead candidate targets chronic hypoparathyroidism, a rare hormone disorder. The company is also developing treatments for obesity and for low blood sugar after weight loss surgery. Its candidates are still in development, and its intended users are patients with these conditions.

Headquarters
Carmel, IN